FY2029 Earnings Estimate for Genelux Issued By HC Wainwright

Genelux Corporation (NASDAQ:GNLX) – HC Wainwright raised their FY2029 earnings per share (EPS) estimates for Genelux in a research note issued on Friday, March 20th. HC Wainwright analyst E. Bodnar now expects that the company will earn $1.66 per share for the year, up from their previous estimate of $1.61. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s FY2030 earnings at $2.58 EPS.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.01 million for the quarter.

GNLX has been the subject of a number of other reports. Wall Street Zen raised shares of Genelux from a “sell” rating to a “hold” rating in a research note on Saturday. Benchmark dropped their target price on Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a report on Friday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Genelux currently has an average rating of “Moderate Buy” and a consensus target price of $20.40.

Genelux Stock Up 3.3%

Shares of GNLX opened at $2.48 on Monday. The firm has a market capitalization of $111.13 million, a PE ratio of -2.88 and a beta of 0.15. The firm has a 50-day moving average price of $2.68 and a 200 day moving average price of $4.14. Genelux has a 52-week low of $1.99 and a 52-week high of $8.53.

Insider Buying and Selling at Genelux

In other news, Director John Thomas sold 10,000 shares of Genelux stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $2.90, for a total value of $29,000.00. Following the transaction, the director owned 482,784 shares of the company’s stock, valued at $1,400,073.60. The trade was a 2.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Genelux

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. bought a new stake in Genelux during the first quarter worth approximately $239,000. Jane Street Group LLC bought a new position in shares of Genelux in the first quarter valued at $190,000. Geode Capital Management LLC lifted its position in shares of Genelux by 1.8% during the 2nd quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock valued at $915,000 after acquiring an additional 5,596 shares during the last quarter. MAI Capital Management lifted its position in shares of Genelux by 66,161.3% during the 2nd quarter. MAI Capital Management now owns 236,553 shares of the company’s stock valued at $679,000 after acquiring an additional 236,196 shares during the last quarter. Finally, Private Management Group Inc. bought a new stake in shares of Genelux during the 2nd quarter worth $33,000. 37.33% of the stock is owned by institutional investors and hedge funds.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.